DGAP-News

MOLOGEN AG: Grant to collaboration partner for combination study in HIV with lead product lefitolimod - Seite 2

the patient's body to prevent further infection and eliminate infected
cells. Lefitolimod and the new antibodies have been tested individually; no
combination studies were conducted so far.

HIV infects the immune system and destroys or affects the proper function
of immune cells. Without antiretroviral treatment, this eventually leads to
acquired immune deficiency syndrome (AIDS) and the immune system can no
longer fend off a wide range of infections and diseases. HIV remains a
serious worldwide health issue. According to estimates by WHO and UNAIDS
(United Nations Programme on AIDS) 37 million people worldwide were living
with HIV at the end of 2015. Some 2 million people became newly infected in
that same year, and 1.1 million died as a result of HIV-related causes
globally.

MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the
treatment of infectious diseases.

The cancer immunotherapy lefitolimod (MGN1703) is the company's lead
product and best-in-class TLR9 agonist. Treatment with lefitolimod
(MGN1703) triggers a broad and strong activation of the immune system. Due
to this mode of action, namely to reactivate the monitoring function of the
immune system, lefitolimod (MGN1703) can be recognized as an Immune
Surveillance Reactivator (ISR). It has the potential to be applied to
various indications. ISR lefitolimod (MGN1703) is currently being developed
for first-line maintenance treatment of colorectal cancer (pivotal study)
and small cell lung cancer (randomized controlled trial). Furthermore, it
is also being investigated in an extended phase I study in HIV and a phase
I combination study with the checkpoint inhibitor ipilimumab (Yervoy(R)).
Next to checkpoint inhibitors, lefitolimod is one of the few product
candidates that are in a phase III clinical trial (IMPALA) in the field of
immuno-oncology and close to reaching the market.

MOLOGEN's pipeline focus is on new, innovative immunotherapies to treat
diseases for which there is a high medical need.

www.mologen.com


Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of